|05/04/17||The Medicines Company to Participate in the Bank of America Merrill Lynch 2017 Health Care Conference|
|PARSIPPANY, N.J.--(BUSINESS WIRE)--May 4, 2017--
The Medicines Company (NASDAQ:MDCO) today announced that it will
participate in the Bank of America Merrill Lynch 2017 Health Care
Conference on Tuesday, May 16, 2017, in Las Vegas, Nevada. Clive
Meanwell, M.D., Ph.D., Chief Executive Officer, will participate in a
fireside chat at 8:00 a.m., Pacific Daylight Time.
A live audio webcast will be available in the
|04/26/17||The Medicines Company Reports First-Quarter 2017 Financial Results|
|PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 26, 2017--
The Medicines Company (NASDAQ:MDCO) today announced its business and
financial results for the first-quarter ended March 31, 2017.
“During the first quarter of 2017, The Medicine Company continued to
deliver excellent execution against our 2017 objectives, significantly
advancing key development programs, strictly managing cash deployment to
enhance our ability to support our products and pipelin... |
|04/26/17||The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran|
|— Pivotal trials will enroll approximately 1,500 subjects randomized
to inclisiran versus approximately 1,500 subjects randomized to placebo,
with a primary endpoint of LDL-C and an 18-month study period —
— NDA submission anticipated at or around the end of 2019 —
PARSIPPANY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 26, 2017--
The Medicines Company (NASDAQ:MDCO) and Alnylam Pharmaceuticals, Inc.
(NASDAQ:ALNY) today announced that T... |
|04/17/17||The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam|
|PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 17, 2017--
Company (NASDAQ:MDCO) today announced that data from its portfolio
of antimicrobial products and late-stage product candidates will be
featured in presentations at the 27th Annual European
Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2017)
to be held April 22-25, 2017, in Vienna, Austria.
The Company will present data on its investigational antibiotic,